Impact of Adjuvant Chemotherapy on Resected Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: Results From an International Multicenter Study

Almost half of patients with resected IPMN-derived PDAC may be overtreated or undertreated. In patients with node-negative disease or normal CA19-9, adjuvant chemotherapy is not associated with a survival benefit, whereas those with node-positive disease and elevated CA19-9 have an associated benefit from adjuvant chemotherapy. A decision tree was proposed. Randomized controlled trials are needed for validation.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2024-09-10
DOI
https://doi.org/10.1200/jco.23.02313
Citations
20
Primary Topic
Pancreatic and Hepatic Oncology Research
Type
article
Field-Weighted Citation Impact
5.65
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Impact of Adjuvant Chemotherapy on Resected Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: Results From an International Multicenter Study

Thilo Hackert, Antonio Pea, Marie Hecker, Lily V. Saadat et al.
20 citations
Journal of Clinical Oncology
Pancreatic and Hepatic Oncology Research
5.65
article

Impact of Adjuvant Chemotherapy on Resected Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: Results From an International Multicenter Study

Thilo Hackert, Antonio Pea, Marie Hecker, Lily V. Saadat, Matthew H. G. Katz, Marc G. Besselink, C. Max Schmidt, Paul E. Oberstein, Nader Hanna, Isabella M. Frigerio, Valentina Allegrini, Kelly J. Lafaro, Jörg Kaiser, Giovanni Marchegiani, Rachel C. Kim, Markus W. Büchler, Shailesh V. Shrikhande, Peter J. Allen, Benedict Kinny‐Köster, Michael P. Kim, Myrte Gorris, Massimo Arcerito, Christopher L. Wolfgang, Joseph R. Habib, Kevin C. Soares, Chanjuan Shi, Lois A. Daamen, Floortje van Oosten, Shuichi Watanabe, Camilo Correa‐Gallego, Jin Peng He, Ammar A. Javed, Jeremy Sharib, Yi Miao, Giovanni Butturini, Min Tu, Mahip Grewal, Marco Del Chiaro, Roberto Salvia, Carlos Fernández-del Castillo, I. Quintus Molenaar, Laura R. Prakash, Manish Bhandre, Martin Loos, Poitr Zelga
article en
20 citations

Abstract

Almost half of patients with resected IPMN-derived PDAC may be overtreated or undertreated. In patients with node-negative disease or normal CA19-9, adjuvant chemotherapy is not associated with a survival benefit, whereas those with node-positive disease and elevated CA19-9 have an associated benefit from adjuvant chemotherapy. A decision tree was proposed. Randomized controlled trials are needed for validation.

Journal of Clinical OncologyVol. 42(36)
Champalimaud Foundation (PT), University of Verona (IT), University of Maryland, Baltimore (US), University of Maryland Medical Center (US), Memorial Sloan Kettering Cancer Center (US), The University of Texas MD Anderson Cancer Center (US), University of Padua (IT), Johns Hopkins University (US), Universität Hamburg (DE), Heidelberg University (DE), Johns Hopkins Medicine (US), Tata Memorial Hospital (IN), University Hospital Heidelberg (DE), University Medical Center Utrecht (NL), Massachusetts General Hospital (US), University Medical Center Hamburg-Eppendorf (DE), Amsterdam University Medical Centers (NL), Duke University Hospital (US), Indiana University School of Medicine, University of Colorado Anschutz Medical Campus (US), Indiana University – Purdue University Indianapolis (US), New York University (US), Nanjing Medical University (CN)
Good health and well-being
Openalex Percentile: Top 3%
Pancreatic and Hepatic Oncology Research
5.65
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.